Inventor · disambiguated record
Erica Carrier
Also filed as: CARRIER ERICA · CARRIER ERICA J
9 granted patents·15 pending applications·7 citations·filing 2015–2024
82Inventor score
Top patents by PatentIndex Score
24 records- 0188US2025114334A1Ifetroban Treatment for Systemic SclerosisCUMBERLAND PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 0285US9693998B2Compositions and methods of treating cardiac fibrosis with ifetrobanCUMBERLAND PHARMACEUTICALS INC·Filed 2015·Granted Jul 4, 2017·4 cites·20 claims
- 0384US2023381147A1Ifetroban Treatment for Systemic SclerosisCUMBERLAND PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 0478US12161632B2Compositions and methods of treating cardiac fibrosis with ifetrobanCUMBERLAND PHARMACEUTICALS INC·Filed 2023·Granted Dec 10, 2024·0 cites·10 claims
- 0578US10314824B2Compositions and methods of treating cardiac fibrosis with ifetrobanCUMBERLAND PHARMACEUTICALS INC·Filed 2018·Granted Jun 11, 2019·1 cites·9 claims
- 0678US10064845B2Compositions and methods of treating muscular dystrophy with thromboxane-A2 receptor antagonistsCUMBERLAND PHARMACEUTICALS INC·Filed 2017·Granted Sep 4, 2018·2 cites·22 claims
- 0777US2022133696A1Ifetroban Treatment for Systemic SclerosisCUMBERLAND PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 0876US2025049764A1Compositions and Methods of Treating Cardiac Fibrosis with IfetrobanCUMBERLAND PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 0973US2021137895A1Compositions and Methods of Treating Cardiac Fibrosis with IfetrobanCUMBERLAND PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 1072US10925860B2Compositions and methods of treating cardiac fibrosis with ifetrobanCUMBERLAND PHARMACEUTICALS INC·Filed 2020·Granted Feb 23, 2021·0 cites·7 claims
- 1171US2021015798A1Ifetroban Treatment for Systemic SclerosisCUMBERLAND PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 1270US2020253935A1Ifetroban Treatment for Systemic SclerosisCUMBERLAND PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 1369US10583126B2Compositions and methods of treating cardiac fibrosis with ifetrobanCUMBERLAND PHARMACEUTICALS INC·Filed 2019·Granted Mar 10, 2020·0 cites·7 claims
- 1468US2020113872A1Ifetroban Treatment for Systemic SclerosisCUMBERLAND PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 1567US2019343809A1Ifetroban Treatment for Systemic SclerosisCUMBERLAND PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 1665US2019117628A1Ifetroban Treatment for Systemic SclerosisCUMBERLAND PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 1764US10016399B2Compositions and methods of treating cardiac fibrosis with ifetrobanCUMBERLAND PHARMACEUTICALS INC·Filed 2017·Granted Jul 10, 2018·0 cites·19 claims
- 1863US10456380B2Compositions and methods of treating muscular dystrophy with thromboxane-A2 receptor antagonistsCUMBERLAND PHARMACEUTICALS INC·Filed 2019·Granted Oct 29, 2019·0 cites·20 claims
- 1961US2017312255A1Ifetroban treatment for systemic sclerosisCUMBERLAND PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 2060US2020030298A1Compositions and Methods of Treating Muscular Dystrophy with Thromboxane-A2 Receptor AntagonistsCUMBERLAND PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 2159US2024000726A1Compounds and methods for scavenging dicarbonyl electrophilesUNIV VANDERBILT·Filed 2023·Application pending·0 cites
- 2257US2018353481A1Compositions and Methods of Treating Muscular Dystrophy with Thromboxane-A2 Receptor AntagonistsCUMBERLAND PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 2345US11696903B2Compounds and methods for scavenging dicarbonyl electrophilesUNIV VANDERBILT·Filed 2020·Granted Jul 11, 2023·0 cites·19 claims
- 2437US2015265584A1Levuglandin adducts histone h4 in a cyclooxygenase-2-dependent manner, altering its interaction with dnaUNIV VANDERBILT·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Erica Carrier files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →